Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.49 |
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545007 | 1.00 | ACHE (0.55) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL14545572 | 0.94 | ACHE (0.62) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL4868726 | 0.78 | ROCK2 (0.56) | ACHEBACE1BCHEROCK2CCR2 | |
| SCHEMBL14544974 | 0.77 | IKBKB (0.56) | ACHECNR1 | |
| SCHEMBL14545327 | 0.77 | MCHR1 (0.46) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL26118339 | 0.77 | ACHE (0.56) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL28894880 | 0.75 | LMNA (0.55) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL30085615 | 0.75 | LMNA (0.55) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL13326542 | 0.74 | DRD2 (0.65) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL14545335 | 0.74 | ACHE (0.49) | ACHEBACE1BCHEDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | ACHE 1931/4885BACE1 1414/4885BCHE 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.